老年乳腺癌单用激素治疗与激素治疗联合放疗的人群研究
该研究基于不列颠哥伦比亚1999-2009年70-79岁、1期雌激素受体阳性乳腺癌保乳术后患者,比较CALGB 9343发表前后辅助治疗模式。结果显示放疗联合激素治疗使用率未变(91% vs 89%,P=.4),单用激素治疗10年局部区域无复发生存率90%低于联合组98%(P=.01),但乳腺癌特异性生存率无差异(95% vs 96%,P=.2)。
要点
- CALGB发表后放疗联合激素治疗使用率无显著变化(91% vs 89%,P=.4)。
- 单用激素治疗10年局部区域无复发生存率90%,联合组98%(P=.01)。
- 10年乳腺癌特异性生存率两组无差异(95% vs 96%,P=.2)。
核心结论
- 患者结局与CALGB试验接近,提示其结果可推广至激素依从性典型的老年乳腺癌人群。
- CALGB试验结果及实践指南未改变本人群中辅助放疗联合激素治疗的使用。
研究设计与样本
- 基于人群的队列研究,纳入1999-2009年保乳术后70-79岁、1期雌激素受体阳性乳腺癌患者。
- 比较CALGB发表前(1999-2003)与后(2005-2009)两个时期辅助治疗使用情况。
- 采用Kaplan-Meier分析和Cox回归分析生存终点,Fine和Gray方法处理非乳腺癌死亡竞争风险。
主要发现
- 放疗联合激素治疗使用率在CALGB发表前为91%(n=319),发表后为89%(n=403),P=.4。
- 单用激素治疗组1年激素依从率为75%,4年为55%。
- 10年局部区域无复发生存率联合组98%,单用组90%(P=.01)。
- 10年乳腺癌特异性生存率联合组96%,单用组95%(P=.2)。
- 组织学3级或淋巴血管侵犯患者无事件生存率更低;多因素分析中治疗类型不预测总生存(P=.3)。
关键数值与推荐
- 激素依从性定义为配发处方激素治疗药物的80%。
- 采用Charlson评分量化合并症。
临床怎么用
- 在激素依从性典型的老年早期乳腺癌患者中,CALGB 9343结果可推广,支持单用激素治疗作为选项。
- 放疗联合激素治疗可改善局部区域控制,但未显著改善乳腺癌特异性生存或总生存。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: The Cancer and Leukemia Group B (CALGB) 9343 trial randomized elderly women with estrogen receptor-positive, stage 1 breast cancer to receive either hormone therapy (HT) or HT and radiation therapy (HT-RT) after lumpectomy and showed no difference in survival. After this publication, a practice guideline made HT alone a standard treatment option in British Columbia. The subsequent population-based pattern of practice was studied. METHODS AND MATERIALS: All women aged 70 to 79 years, referred after lumpectomy from 1999 to 2009, with stage 1, estrogen receptor-positive breast cancer were identified. The use of adjuvant HT or HT-RT was evaluated in 2 eras: before (1999-2003) and after (2005-2009) the CALGB publication. The proportion receiving each treatment in these eras was determined. Kaplan-Meier analyses with Cox regression were used for survival endpoints. The Fine and Gray method was used with non-breast cancer death as a competing risk for event-free survival. The Charlson score was used to quantify comorbidity. Adherence was defined as dispensation of 80% of prescribed HT. RESULTS: HT-RT was used in 91% of patients before (n=319) and 89% of patients after (n=403) the CALGB publication (P=.4). In the HT-alone group, the rate of HT adherence was 75% at 1 year and 55% at 4 years. The 10-year locoregional recurrence-free survival rate was 98% with HT-RT and 90% with HT alone (P=.01), whereas the 10-year breast cancer-specific survival rate was 96% with HT-RT and 95% with HT alone (P=.2). Patients with grade 3 histology or lymphovascular invasion were more likely to have low event-free survival. On multivariate analysis, treatment type did not predict overall survival (P=.3). CONCLUSIONS: Our patient outcomes closely matched those of the CALGB trial, suggesting that its results are generalizable to a population of elderly breast cancer patients with typical HT adherence. The CALGB trial results, as well as the resulting practice guideline, did not change the use of adjuvant HT-RT in our population-based cancer program.
引用
- Nichol AM, Chan EK, Lucas S, et al. The Use of Hormone Therapy Alone Versus Hormone Therapy and Radiation Therapy for Breast Cancer in Elderly Women: A Population-Based Study. Int J Radiat Oncol Biol Phys. 2017. PMID: 28602413. doi:10.1016/j.ijrobp.2017.02.094
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。